An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Metenkefalin/tridecactide (Primary)
- Indications COVID 2019 infections; Pneumonia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 23 Dec 2020 Status changed from active, no longer recruiting to completed.
- 01 Oct 2020 Planned End Date changed from 31 Oct 2020 to 31 Dec 2020.
- 01 Oct 2020 Planned primary completion date changed from 31 Aug 2020 to 31 Oct 2020.